ADMA BiologicsADMA.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, ADMA Biologics (ADMA.O) trades at a P/E of 14.20x, P/B of 5.90x, P/S of 4.67x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 22nd percentile over the trailing 10Y window (vs. 22nd percentile over 3Y); P/B sits at the 52nd percentile over the trailing 10Y window (vs. 24th percentile over 3Y); P/S sits at the 31st percentile over the trailing 10Y window (vs. 29th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 22nd percentile within its industry and the 35th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.34%, ranking at the 96th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 30.3 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. ADMA Biologics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: ADMA · ADMA
Want the full picture on whether ADMA Biologics (ADMA.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 14.20 | ||||||
| P/B (MRQ) | 5.90 | ||||||
| P/S (TTM) | 4.67 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.34% |